Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Chinese National Intellectual Property Administration for its breast cancer vaccine technology patent. This marks the company's first Chinese patent and will provide protection into the 2040s.

The patent, exclusively licensed from Cleveland Clinic, covers composition of matter protection for Anixa's novel breast cancer treatment and prevention approach. The vaccine targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain breast cancers.

This expansion is particularly significant as breast cancer has become the most commonly diagnosed cancer among women in China, with hundreds of thousands of new cases annually. The patent complements existing protection in the United States and other key global markets.

Positive

• Secured first Chinese patent protection for breast cancer vaccine technology extending into 2040s
• Expands intellectual property coverage in one of world's largest and fastest-growing patient markets
• Strategic positioning in China where breast cancer is the most commonly diagnosed cancer among women
• Complements existing patents in US and other key global markets

Negative

• None.

Insights

Biotechnology Patent Expert

Anixa's new Chinese patent significantly expands global IP protection for its breast cancer vaccine, strengthening long-term commercial potential in a massive market.

This Chinese patent allowance represents a strategic expansion of Anixa's intellectual property portfolio into one of the world's largest healthcare markets. Securing composition of matter protection—the strongest form of pharmaceutical patent—provides Anixa exclusive rights to their breast cancer vaccine technology in China until at least the 2040s. This 20+ year exclusivity window is particularly valuable for a preventative cancer vaccine, as it allows sufficient time for clinical development, regulatory approval, and commercial exploitation.

The timing is especially significant considering China's rapidly growing breast cancer burden. Unlike the patent portfolios of many biotechs that focus primarily on Western markets, Anixa is building comprehensive global coverage aligned with disease epidemiology. This patent complements existing protection in the US and other jurisdictions, creating a more licensable and commercially valuable global IP estate.

The underlying technology—targeting α-lactalbumin, a protein normally only expressed during lactation but aberrantly expressed in certain breast cancers—employs a clever "retired protein" strategy. This approach potentially enables selective immune targeting while minimizing off-target effects, addressing a fundamental challenge in cancer vaccine development.

For investors, this patent allowance indicates reduced competition risk in a key market and enhanced partnership potential with Chinese pharmaceutical companies, who strongly prefer technologies with local patent protection. While still in clinical development, this strategic IP expansion positions Anixa to capture value from China's growing focus on innovative preventative oncology technologies.

Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine

Expands global intellectual property coverage in markets with high breast cancer incidence

New patent will provide IP protection of Breast Cancer Vaccine in China into at least the 2040s

SAN JOSE, Calif., Aug. 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Chinese National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in China.

With this allowance, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Chinese patent complements patents issued in the United States and other key global jurisdictions, and represents an important step toward future regulatory and commercial efforts outside the U.S.

"This newly allowed patent further illustrates the continued recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue advancing clinical development in the U.S., this allowance further strengthens our ability to pursue strategic global opportunities in regions with a high burden of breast cancer."

Breast cancer has become the most commonly diagnosed cancer among women in China, with incidence rising steadily over the past two decades and hundreds of thousands of new cases each year. As one of the world's largest and fastest-growing patient populations, addressing this challenge is a critical public health priority, requiring innovative preventative solutions such as Anixa's vaccine.

Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue.

By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-chinese-national-intellectual-property-administration-for-patent-covering-breast-cancer-vaccine-technology-302533982.html

SOURCE Anixa Biosciences, Inc.

FAQ

What patent did Anixa Biosciences (NASDAQ: ANIX) receive in China?

Anixa received a Notice of Allowance from the Chinese National Intellectual Property Administration for its breast cancer vaccine technology patent, providing composition of matter protection into the 2040s.

How does Anixa's breast cancer vaccine technology work?

The vaccine targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain breast cancers. This 'retired' protein strategy aims to prime the immune system to prevent tumor formation while avoiding harm to normal tissue.

Why is the Chinese patent important for Anixa Biosciences?

The patent is crucial because breast cancer is the most commonly diagnosed cancer among women in China, representing one of the world's largest and fastest-growing patient populations.

Who developed the breast cancer vaccine technology licensed to Anixa?

The vaccine technology was developed at Cleveland Clinic and is exclusively licensed to Anixa Biosciences.

What is the current development status of Anixa's breast cancer vaccine?

The vaccine is currently in clinical development in the United States, while the company pursues strategic global opportunities in other regions.